Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PD-1 Antibody, Peg-Asparaginase, Chidamide Combined With Radiotherapy for the First-line Treatment of Patients With Stage I/II Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL): An Open-label, Multicenter, Phase II Trial

Next Previous
Search
Trial Profile

Anti-PD-1 Antibody, Peg-Asparaginase, Chidamide Combined With Radiotherapy for the First-line Treatment of Patients With Stage I/II Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL): An Open-label, Multicenter, Phase II Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegaspargase (Primary) ; Programmed cell death 1 receptor antagonists (Primary) ; Tucidinostat (Primary)
  • Indications Extranodal NK-T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Jun 2023 Results (n=37) assessing safety and efficacy of chidamide, tislelizumab, and pegaspargase in combination with radiotherapy as first-line treatment in high-risk stage I/II ENKTL presented at the 28th Congress of the European Haematology Association
    • 02 Jul 2020 Status changed from not yet recruiting to recruiting.
    • 09 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top